Verve Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2018 · IPO 2021

Focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary MoreLess

Verve Therapeutics is a pioneering genetic medicines company focused on transforming the treatment of cardiovascular disease through innovative gene editing technologies. The company operates in the biotechnology sector, specifically targeting cardiovascular health. Verve's business model revolves around discovering and developing single-course gene editing medicines that aim to provide long-term solutions for patients, as opposed to traditional chronic management therapies. The initial programs target the PCSK9 and ANGPTL3 genes, which are well-validated for their roles in lowering blood lipid levels. Verve Therapeutics primarily serves patients suffering from cardiovascular diseases, offering them potentially curative treatments. The company generates revenue through the development and commercialization of its gene editing therapies, as well as potential partnerships and collaborations with other biotech firms and healthcare providers.

Keywords: gene editing, cardiovascular disease, biotechnology, PCSK9, ANGPTL3, single-course treatment, genetic medicines, lipid lowering, innovative therapies, healthcare.

Valuation $566M

Revenue $32M

Headcount 100–500

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Talent graph

Verve Therapeutics's talent

Book a demo to see the people

Employees mapped 159 incl. 2 AI specialists

Founders /100 quality score

Key operators 7 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on Verve Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 14 investors entered at this stage

Biomatics Capital Partners

ARCH Venture Partners

Casdin Capital

F-Prime

Wellington Management

Redmile Group

Cormorant Asset Management

RA Capital Management

Janus Henderson Investors

Logos Capital

Rock Springs Capital

Novo Holdings

Citadel

Series B+ 1 investor entered at this stage

Eli Lilly

Global footprint

Where Verve Therapeutics has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

15K monthly visits
across markets

🇺🇸 United States40.7%

🇮🇳 India16%

🇨🇦 Canada13.3%

🇬🇧 United Kingdom12.7%

🇸🇬 Singapore6.7%

Top 5 markets shown

Patent intelligence

$21M patent portfolio · 11 active families

Estimated portfolio value

$21M

3.7% of market cap · 38.1× smaller than top peer BioNTech ($788M)

11 active patent families

Where Verve Therapeutics innovates BioinformaticsCell biologyCoronary arteriesIn vivoMolecular biology

Where Verve Therapeutics concentrates vs peers

Each axis is a top-10 topic across Verve Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Verve Therapeutics

An AI-synthesized read of the highest-engagement posts about Verve Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Verve Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles